Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR7 | Q9NYK1 | 20/20 | 0.78 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.74 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.68 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21660181 | 0.93 | TLR7 (0.78) | TLR7KCNH2CYP3A4CYP2D6 | |
| SCHEMBL21660170 | 0.88 | TLR7 (1.00) | TLR7KCNH2CYP3A4CYP2D6 | |
| SCHEMBL21660254 | 0.87 | TLR7 (0.82) | TLR7KCNH2 | |
| SCHEMBL30341157 | 0.86 | TLR7 (0.89) | TLR7KCNH2CYP3A4CYP2D6 | |
| SCHEMBL23718970 | 0.85 | TLR7 (0.66) | TLR7KCNH2CYP3A4CYP2D6 | |
| SCHEMBL21644766 | 0.84 | TLR7 (0.68) | TLR7KCNH2CYP3A4CYP2D6 | |
| SCHEMBL21660423 | 0.83 | TLR7 (0.86) | TLR7KCNH2CYP3A4CYP2D6 | |
| SCHEMBL23730239 | 0.81 | TLR7 (0.75) | TLR7KCNH2CYP3A4CYP2D6 | |
| SCHEMBL21660194 | 0.81 | TLR7 (1.00) | TLR7KCNH2CYP3A4CYP2D6 | |
| SCHEMBL23718919 | 0.81 | TLR7 (0.86) | TLR7KCNH2CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230140047-A1 | 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS AND METHODS AND USES THEREFOR | BRISTOL-MYERS SQUIBB COMPANY | 2023-05-04 | — | — | US | disclosed |
| US-20200038403-A1 | 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS AND METHODS AND USES THEREFOR | BRISTOL-MYERS SQUIBB COMPANY | 2020-02-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230140047-A1 | 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS AND METHODS AND USES THEREFOR | TLR7, TLR1, TLR9 | TLR7 1/4885KCNH2 3884/4885CYP3A4 4118/4885 |
| US-20200038403-A1 | 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS AND METHODS AND USES THEREFOR | TLR7, TLR1, TLR9 | TLR7 1/4885KCNH2 3884/4885CYP3A4 4118/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.